PEB.NZX
Pacific Edge Limited
Our view
You need to become a client or login to see Forsyth Barr’s current view.
Recent research View all research
About Pacific Edge Limited
Pacific Edge is a cancer diagnostics company in the early stages of commercialisation of its first product, Cxbladder, after 10 years of research into genetic markers. Cxbladder is a suite of non-invasive urine tests to detect the presence of bladder cancer in patients presenting with haematuria. PEB has four Cxbladder products in the market: Detect, Triage, Monitor and Resolve. PEB also has a suite of products in various stages of development for melanoma, colorectal cancer, endometrial cancer and gastric cancer.
Forsyth Barr Analyst
-
Chelsea Leadbetter, Senior Analyst, Equities
[email protected]
DDI: +64 4 495 5262
Share price performance
All stock prices and news delayed 20 minutes
08:48 December 16th 2018 NZDT
0.35 1.5%
0.35 Buy
0.36 Sell
Last 0.35
Open 0.35
High 0.35
Low 0.35
Volume 49,139
Turnover $16,993
Most recent trades All trades for the day
| Time | Price | Volume | Value |
|---|---|---|---|
| 16:25 | 0.35 | 5,125 | $1,768.13 |
| 15:10 | 0.35 | 2,457 | $859.95 |
| 12:45 | 0.35 | 2,771 | $969.85 |
| 11:15 | 0.35 | 2,700 | $945.00 |
| 10:00 | 0.35 | 4,612 | $1,591.14 |
Latest Pacific Edge Limited research
Today's trades
| Trade Number | Time | Price | Volume | Value |
|---|---|---|---|---|
| 7 | 16:25 | 0.35 | 5,125 | $1,768.13 |
| 6 | 15:10 | 0.35 | 2,457 | $859.95 |
| 5 | 12:45 | 0.35 | 2,771 | $969.85 |
| 4 | 11:15 | 0.35 | 2,700 | $945.00 |
| 3 | 10:00 | 0.35 | 4,612 | $1,591.14 |
| 2 | 10:00 | 0.35 | 5,388 | $1,858.86 |
| 1 | 10:00 | 0.35 | 8,500 | $2,932.50 |